S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Pentagon Consultant—Here's how Biden Wins Landslide Re-election (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Forecast, Price & News

$4.93
+0.12 (+2.49%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.69
$5.00
50-Day Range
$4.50
$5.50
52-Week Range
$2.80
$6.19
Volume
47,730 shs
Average Volume
57,177 shs
Market Capitalization
$60.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.15

Gain Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
65.3% Upside
$8.15 Price Target
Short Interest
Healthy
0.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

304th out of 983 stocks

Pharmaceutical Preparations Industry

134th out of 486 stocks


GANX stock logo

About Gain Therapeutics (NASDAQ:GANX) Stock

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GANX Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Where Gain Therapeutics Stands With Analysts
Analyst Expectations for Gain Therapeutics's Future
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
BTIG Keeps Their Buy Rating on Gain Therapeutics (GANX)
See More Headlines

GANX Price History

GANX Company Calendar

Last Earnings
3/23/2023
Today
6/03/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GANX
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.15
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+65.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-17,590,000.00
Pretax Margin
-12,898.67%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
$1.23 per share

Miscellaneous

Free Float
10,973,000
Market Cap
$60.79 million
Optionable
Not Optionable
Beta
0.37

Key Executives

  • Dr. Khalid Islam Ph.D. (Age 67)
    Founder & Chairman
    Comp: $60k
  • Mr. Matthias Alder LIC. IUR. (Age 57)
    LL.M., COO, CEO & Director
    Comp: $414.29k
  • Mr. Salvatore Calabrese (Age 52)
    CFO & Corp. Sec.
    Comp: $345.39k
  • Mr. Gianluca Fuggetta (Age 34)
    Principal Accounting Officer
  • Dr. Xavier Barril Ph.D.
    Chief Technology Officer
  • Dr. Manolo Bellotto Ph.D. (Age 51)
    GM & Chief Strategy Officer
  • Dr. Ana Maria Garcia-Collazo Ph.D.
    Head of Research
  • Dr. Natalia Perez-Carmona Ph.D.
    Head of Biology
  • Dr. Joanne Taylor Ph.D.
    Sr. VP of Research & Scientific Advisor
  • Dr. Terenzio Ignoni Pharm.D.
    Sr. VP of Technical Operations













GANX Stock - Frequently Asked Questions

Should I buy or sell Gain Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GANX shares.
View GANX analyst ratings
or view top-rated stocks.

What is Gain Therapeutics' stock price forecast for 2023?

5 brokerages have issued 1-year price targets for Gain Therapeutics' shares. Their GANX share price forecasts range from $5.00 to $10.00. On average, they predict the company's share price to reach $8.15 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price.
View analysts price targets for GANX
or view top-rated stocks among Wall Street analysts.

How have GANX shares performed in 2023?

Gain Therapeutics' stock was trading at $3.13 at the beginning of 2023. Since then, GANX stock has increased by 57.5% and is now trading at $4.93.
View the best growth stocks for 2023 here
.

Are investors shorting Gain Therapeutics?

Gain Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 55,100 shares, a decline of 7.9% from the April 30th total of 59,800 shares. Based on an average trading volume of 83,600 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.6% of the shares of the stock are sold short.
View Gain Therapeutics' Short Interest
.

When is Gain Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our GANX earnings forecast
.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02.

When did Gain Therapeutics IPO?

(GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

What is Gain Therapeutics' stock symbol?

Gain Therapeutics trades on the NASDAQ under the ticker symbol "GANX."

Who are Gain Therapeutics' major shareholders?

Gain Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.77%), CM Management LLC (0.74%), Renaissance Technologies LLC (0.32%), Raymond James & Associates (0.17%), Dimensional Fund Advisors LP (0.15%) and Susquehanna International Group LLP (0.12%).
View institutional ownership trends
.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gain Therapeutics' stock price today?

One share of GANX stock can currently be purchased for approximately $4.93.

How much money does Gain Therapeutics make?

Gain Therapeutics (NASDAQ:GANX) has a market capitalization of $60.79 million and generates $140,000.00 in revenue each year. The company earns $-17,590,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How can I contact Gain Therapeutics?

Gain Therapeutics' mailing address is 4800 HAMPDEN LANE SUITE 200, BETHESDA MD, 20814. The official website for the company is www.gaintherapeutics.com. The company can be reached via phone at 301-500-1556 or via email at ir@gaintherapeutics.com.

This page (NASDAQ:GANX) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -